Verona Pharma PLC American Depositary Share (VRNA) Competitors $105.27 +0.07 (+0.07%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$105.30 +0.03 (+0.03%) As of 08/14/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRNA vs. ONC, BNTX, INSM, SMMT, TEVA, GMAB, ASND, VTRS, RDY, and QGENShould you be buying Verona Pharma PLC American Depositary Share stock or one of its competitors? The main competitors of Verona Pharma PLC American Depositary Share include BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Verona Pharma PLC American Depositary Share vs. Its Competitors BeOne Medicines BioNTech Insmed Summit Therapeutics Teva Pharmaceutical Industries Genmab A/S Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Qiagen BeOne Medicines (NASDAQ:ONC) and Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation. Is ONC or VRNA more profitable? BeOne Medicines has a net margin of -3.89% compared to Verona Pharma PLC American Depositary Share's net margin of -36.62%. BeOne Medicines' return on equity of -1.22% beat Verona Pharma PLC American Depositary Share's return on equity.Company Net Margins Return on Equity Return on Assets BeOne Medicines-3.89% -1.22% -0.72% Verona Pharma PLC American Depositary Share -36.62%-21.12%-9.07% Which has better valuation and earnings, ONC or VRNA? Verona Pharma PLC American Depositary Share has lower revenue, but higher earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Verona Pharma PLC American Depositary Share, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeOne Medicines$3.81B8.91-$644.79M-$1.73-179.01Verona Pharma PLC American Depositary Share$42.28M211.96-$173.42M-$0.99-106.33 Which has more risk & volatility, ONC or VRNA? BeOne Medicines has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Verona Pharma PLC American Depositary Share has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Do analysts rate ONC or VRNA? BeOne Medicines presently has a consensus price target of $330.89, indicating a potential upside of 6.85%. Verona Pharma PLC American Depositary Share has a consensus price target of $109.00, indicating a potential upside of 3.54%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Verona Pharma PLC American Depositary Share 0 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.15 Do institutionals and insiders believe in ONC or VRNA? 48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by insiders. Comparatively, 4.8% of Verona Pharma PLC American Depositary Share shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer ONC or VRNA? In the previous week, BeOne Medicines and BeOne Medicines both had 8 articles in the media. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.50 beat BeOne Medicines' score of 0.59 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Verona Pharma PLC American Depositary Share 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBeOne Medicines beats Verona Pharma PLC American Depositary Share on 9 of the 15 factors compared between the two stocks. Get Verona Pharma PLC American Depositary Share News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRNA vs. The Competition Export to ExcelMetricVerona Pharma PLC American Depositary ShareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.96B$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-106.3320.4930.2925.74Price / Sales211.96356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book32.198.608.826.15Net Income-$173.42M-$54.65M$3.25B$265.06M7 Day Performance-0.01%5.86%3.70%2.60%1 Month Performance0.48%8.86%5.84%2.83%1 Year Performance286.31%13.33%29.92%25.58% Verona Pharma PLC American Depositary Share Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRNAVerona Pharma PLC American Depositary Share2.3649 of 5 stars$105.27+0.1%$109.00+3.5%+285.5%$8.96B$42.28M-106.3330Short Interest ↓ONCBeOne Medicines0.6668 of 5 stars$289.75+0.5%$330.89+14.2%N/A$31.76B$4.56B-167.4811,000BNTXBioNTech1.7694 of 5 stars$109.26-2.1%$135.91+24.4%+32.8%$26.27B$2.98B-68.296,772Analyst ForecastINSMInsmed4.0303 of 5 stars$112.89+3.0%$112.71-0.2%+70.6%$21.42B$398.11M-19.771,271Trending NewsAnalyst ForecastGap UpSMMTSummit Therapeutics2.3971 of 5 stars$28.25-1.4%$34.67+22.7%+137.9%$20.98BN/A-83.09110Earnings ReportAnalyst ForecastTEVATeva Pharmaceutical Industries3.7012 of 5 stars$16.41+0.3%$24.71+50.6%-2.5%$18.83B$16.54B-102.5836,830GMABGenmab A/S3.9789 of 5 stars$21.08-1.6%$37.80+79.3%-14.3%$13.52B$3.26B10.592,682ASNDAscendis Pharma A/S3.2262 of 5 stars$195.97+2.3%$239.80+22.4%+37.5%$11.98B$393.54M-37.981,017Gap DownVTRSViatris2.223 of 5 stars$9.86+1.6%$10.40+5.5%-6.2%$11.57B$14.74B-3.4032,000Insider TradeRDYDr. Reddy's Laboratories3.0923 of 5 stars$13.81+0.0%$16.95+22.8%-13.3%$11.53B$334.26B20.9227,811News CoverageAnalyst RevisionQGENQiagen3.6503 of 5 stars$48.02-0.1%$49.69+3.5%+9.4%$10.67B$1.98B28.375,765 Related Companies and Tools Related Companies ONC Alternatives BNTX Alternatives INSM Alternatives SMMT Alternatives TEVA Alternatives GMAB Alternatives ASND Alternatives VTRS Alternatives RDY Alternatives QGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRNA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma PLC American Depositary Share Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma PLC American Depositary Share With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access